Metabolic
The GLP-1 research landscape in 2026
8 min read · 21/08/2026
Where incretin research has moved since the first dual agonists, and what comparators labs are using now.
Incretin research has expanded rapidly from single GLP-1 agonism to dual and triple receptor targets.
## Single agonists Semaglutide remains the most widely used reference compound in glucose-handling models.
## Dual agonists Tirzepatide introduced GIP receptor activity alongside GLP-1, and is now a standard comparator.
## What to watch Triple agonists targeting glucagon receptors are the current frontier in published preclinical work.
References
- Incretin-based therapies: preclinical review, Diabetologia
This article is educational and summarises published research. It is not medical advice and does not describe human use. All Pepmol products are supplied for laboratory research only.